227 related articles for article (PubMed ID: 15245776)
1. DT-diaphorase: a target for new anticancer drugs.
Danson S; Ward TH; Butler J; Ranson M
Cancer Treat Rev; 2004 Aug; 30(5):437-49. PubMed ID: 15245776
[TBL] [Abstract][Full Text] [Related]
2. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
Phillips RM; Burger AM; Loadman PM; Jarrett CM; Swaine DJ; Fiebig HH
Cancer Res; 2000 Nov; 60(22):6384-90. PubMed ID: 11103802
[TBL] [Abstract][Full Text] [Related]
3. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
4. DT-diaphorase as a target enzyme for biochemical modulation of mitomycin C.
Saeki S; Nishiyama M; Toge T
Hiroshima J Med Sci; 1995 Sep; 44(3):55-63. PubMed ID: 8567314
[TBL] [Abstract][Full Text] [Related]
5. [DT-diaphorase].
Mikami K; Shirakusa T; Tsuruo T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161
[TBL] [Abstract][Full Text] [Related]
6. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
Gan Y; Mo Y; Kalns JE; Lu J; Danenberg K; Danenberg P; Wientjes MG; Au JL
Clin Cancer Res; 2001 May; 7(5):1313-9. PubMed ID: 11350900
[TBL] [Abstract][Full Text] [Related]
7. Mitomycin C resistance induced by TCF-3 overexpression in gastric cancer cell line MKN28 is associated with DT-diaphorase down-regulation.
Sagara N; Katoh M
Cancer Res; 2000 Nov; 60(21):5959-62. PubMed ID: 11085512
[TBL] [Abstract][Full Text] [Related]
8. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.
Malkinson AM; Siegel D; Forrest GL; Gazdar AF; Oie HK; Chan DC; Bunn PA; Mabry M; Dykes DJ; Harrison SD
Cancer Res; 1992 Sep; 52(17):4752-7. PubMed ID: 1324793
[TBL] [Abstract][Full Text] [Related]
9. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.
Traver RD; Horikoshi T; Danenberg KD; Stadlbauer TH; Danenberg PV; Ross D; Gibson NW
Cancer Res; 1992 Feb; 52(4):797-802. PubMed ID: 1737339
[TBL] [Abstract][Full Text] [Related]
10. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase.
Wang X; Doherty GP; Leith MK; Curphey TJ; Begleiter A
Br J Cancer; 1999 Jun; 80(8):1223-30. PubMed ID: 10376975
[TBL] [Abstract][Full Text] [Related]
11. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
12. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.
Mikami K; Naito M; Tomida A; Yamada M; Sirakusa T; Tsuruo T
Cancer Res; 1996 Jun; 56(12):2823-6. PubMed ID: 8665520
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.
Workman P
Oncol Res; 1994; 6(10-11):461-75. PubMed ID: 7620214
[TBL] [Abstract][Full Text] [Related]
14. Expression of the prodrug-activating enzyme DT-diaphorase via Ad5 delivery to human colon carcinoma cells in vitro.
Misra V; Klamut HJ; Rauth AM
Cancer Gene Ther; 2002 Feb; 9(2):209-17. PubMed ID: 11857040
[TBL] [Abstract][Full Text] [Related]
15. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies.
Ross D; Beall H; Traver RD; Siegel D; Phillips RM; Gibson NW
Oncol Res; 1994; 6(10-11):493-500. PubMed ID: 7620217
[TBL] [Abstract][Full Text] [Related]
16. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
Begleiter A; Leith MK; Curphey TJ; Doherty GP
Oncol Res; 1997; 9(6-7):371-82. PubMed ID: 9406243
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific synergistic therapy of mitomycin C: modulation of bioreductive activation.
Sakamoto N; Toge T; Nishiyama M
Hiroshima J Med Sci; 1997 Jun; 46(2):67-73. PubMed ID: 9232934
[TBL] [Abstract][Full Text] [Related]
18. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.
Powis G; Gasdaska PY; Gallegos A; Sherrill K; Goodman D
Anticancer Res; 1995; 15(4):1141-5. PubMed ID: 7653992
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.
Beall HD; Mulcahy RT; Siegel D; Traver RD; Gibson NW; Ross D
Cancer Res; 1994 Jun; 54(12):3196-201. PubMed ID: 8205540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]